Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Expensive Performer
1082.1500 16.40 (1.54%)
NSE Mar 19, 2025 10:31 AM
Volume: 18,715
 

logo
Alivus Life Sciences Ltd.
29 Apr 2023
1082.15
1.54%
buy
by BOB Capital Markets Ltd.
Target: 600
BOB Capital Markets Ltd.
Q4 revenue of Rs 6.2bn (+21% YoY) beat our estimate by 14% driven by recovery in CDMO and growth in API
 
Alivus Life Sciences Ltd. is trading above all available SMAs
More from Alivus Life Sciences Ltd.
Recommended
Market trades higher, GR Infraprojects bags an order worth Rs 4,262.8 crore from the NHAI
Trendlyne Marketwatch | 19 Mar 2025, 10:32AM
Five stocks to buy from analysts this week - March 18, 2025
The Baseline | 18 Mar 2025, 05:17PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
| 27 Jul 2021